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K e y  M e s s a g e s 
1. Phosphoantigens could protect against influenza 
A (H1N1) virus infection in humanised mice 
with a human immune system.
2. This protection was strain-dependent for avian 
influenza A (H5N1) virus infection.
3. This suggests a novel therapeutic approach 
against influenza by using phosphoantigens to 
inhibit influenza A virus infection.
4. The humanised mouse model provides a low-cost 
Use of humanised mice to study antiviral  
activity of human γδ-T cells against  
influenza A viruses
Introduction
Influenza A virus can cause substantial morbidity 
and mortality. Potential emergence of a new 
pandemic strain (eg avian influenza A virus [H5N1]) 
through natural reassortment is a concern. Both 
innate and adaptive immune systems play critical 
roles in protecting against influenza A viruses, and 
direct manipulation of the host immune system can 
help protect against influenza A virus infections. 
Vaccines targeting the adaptive immune system may 
be less effective against a new pandemic strain. The 
currently available neuraminidase inhibitors may 
become ineffective with the emergence of resistant 
virus strains. Therefore, activating early innate 
responses enables protection against influenza A 
virus infection early after virus exposure. 
 As the first line of the host defence, the antiviral 
activities of γδ−cells against other viruses have 
been demonstrated in different models.1-3 Human 
Vδ2−T cells, representing most peripheral blood 
and lymphoid organ γδ−T cells, can be selectively 
activated and expanded by a phosphoantigen such 
as isopentenyl pyrophosphate, which also triggers 
γδ−T cells to produce interferon-γ and other 
cytokines and chemokines as antiviral activities.2,3 In 
human in vitro systems, phosphatidic acid–activated 
Vδ2−T cells can inhibit virus replication and kill 
virus-infected cells caused by hepatitis C virus and 
severe acute respiratory syndrome coronavirus.4,5 
Whether phosphoantigen-activated Vδ2−T cells 
have antiviral activities against human and avian 
influenza A viruses in vivo remains unknown. 
 Unlike other cells in humans, Vδ2−T cells are 
the dominant γδ−T cells in the circulation, whereas 
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murine γδ−T cells do not express the homologue of 
the Vγδ−T-cell receptor, and no functional equivalent 
for these cells has been identified in mice so far. 
Studies on non-human primates are constrained 
by high costs, limited availability, paucity of genetic 
models for human diseases, and lack of genetically 
inbred strains suitable for cell transplantation. 
Creation of humanised mice that carry partial or 
complete human immune systems may help to 
overcome these obstacles. In this study, conducted 
from August 2007 to July 2009, a humanised mouse 
model was established to investigate the antiviral 
activities of human T cells against human and avian 
influenza A viruses in vivo.
Methods
Generation of humanised mice
C57BL/10SgAiRag2-/-γc-/- mice (Taconic, Hudson, 
NY, USA) were kept in individual ventilated cages in 
the Laboratory Animal Unit of the University of Hong 
Kong. To establish humanised mice models, human 
peripheral blood mononuclear cells (huPBMCs) 
were obtained from healthy donors after approval 
by the Institutional Review Board of the University 
of Hong Kong/Hospital Authority Hong Kong West 
Cluster. Humanised mice were then established 
as previously described with some modifications.6 
All manipulations were in compliance with the 
guidelines for the use of experimental animals. 
Infection of humanised mice with human 
and avian influenza A virus
Under anaesthesia, 10-week-old humanised mice 
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were infected intranasally with the human influenza 
A virus H1N1 (A/Hong Kong/54/98) [25 μL, 
108.4TCID50], mouse-adapted influenza H1N1 
(A/PR/8/34) [25 μL, 1×LD50], and avian influenza 
H5N1 (A/Hong Kong/483/97) or (A/Hong Kong/ 
486/97) [25 μL, 1×LD50]. The weight and survival of 
the infected mice were checked daily post-infection.
Virus titre determination and 
immunohistochemistry assays 
The lungs of infected humanised mice were harvested 
at the indicated time and homogenised with 
phosphate buffered saline (PBS) 2 mL, and the virus 
titre was determined as described previously.7 Lung 
immunohistochemistry staining was performed as 
described previously.8 
Treatment of virus-infected humanised mice
Humanised mice were separated into mock, 
PBS-treated, and drug-treated groups, matched 
according to sex, age, and the source of huPBMCs. 
Four weeks after transplantation of huPBMCs, 
Rag2-/-γc-/- and established humanised mice 
were infected intranasally with human influenza 
H1N1 virus, PR/8 virus, or avian influenza H5N1 
(25 μL, 1×LD50) under anaesthesia. For human 
H1N1 and PR/8 virus infections, phosphoantigen 
or an equivalent volume of PBS was injected 
intraperitoneally on days 3, 5, 7, and 9 after virus 
infection, whereas for avian influenza H5N1 
infection, injections were on days 1, 3, 5, 7, and 9 
after virus infection. Survival was monitored and the 
infected mice were weighed daily; mice with >25% 
weight loss were sacrificed and counted as dying. 
Results
Phosphoantigen-activated cells could efficiently kill 
human and avian influenza H1N1, H9N2, and H5N1 
virus-infected cells and inhibited virus replication 
in vitro.9 We tried to establish the humanised 
mouse model with a human immune system. Using 
immunodeficient C57BL/6Rag2-/-γc-/- mice that lack 
functional T, B, and natural killer (NK) cells, after 4 
weeks of transplantation of huPBMCs, around 80% 
of nucleated cells in peripheral blood were human 
lymphoid cells expressing human CD45 and >20% 
expressed human CD3. Within lymphocytes, cell 
subsets were composed of human T cells (69.4%), 
B cells (5.5%), NK cells (20.0%), and T cells (2.8%). 
Human CD3+ T cells were found in spleen, liver, and 
intestine, but not in lung or kidney of humanised 
mice at 4 weeks post-transplantation. In addition, 
human immunoglobulin G could be detected in 
the humanised mice. The humanised mice could 
survive for >1 year after human immune system 
reconstitution. 
 Using the humanised mouse model, the role 
of γδ−T cells in influenza A virus infection was 
determined in vivo. C57BL/10SgAiRag2-/-γc-/- mice 
were transplanted with huPBMCs or γδ−T cell–
depleted PBMCs. Four weeks later, humanised 
mice were infected intranasally with human H1N1 
influenza A virus. The weight of humanised mice 
were monitored. Although the weight of humanised 
mice decreased significantly after infection, there 
was no significant difference in the weight of 
humanised mice transplanted with huPBMCs or 
γδ−T cell–depleted PBMCs, which indicated that 
unexpanded γδ−T cells had little effect on influenza 
A virus infection.
 The number of Vδ2-T cells could be increased 
8-fold after 2 days of phosphoantigen treatment. 
This suggested that phosphoantigen could expand 
human Vδ2-T cells in vivo.
 To determine whether phosphoantigen could 
be used for treatment of human influenza A virus 
infection in a humanised mouse model, the effect 
of phosphoantigen treatment on human influenza 
H1N1 virus infection in vivo was examined. During 
20 days of observation, humanised mice could be 
effectively infected by human influenza H1N1 virus 
as indicated by the significant weight loss. However, 
for humanised mice treated with phosphoantigen, 
the weight did not decrease at all during this period. 
The phosphoantigen treatment significantly inhibited 
virus replication in the lung compared with the 
control group. Similarly, phosphoantigen treatment 
significantly decreased weight loss and mortality, and 
reduced virus titres in the lung infected with mouse-
adapted influenza H1N1 PR/8 virus.
 Similar to observations in humanised mice 
infected with influenza H1N1 virus, treatment with 
phosphoantigen significantly decreased weight loss 
and mortality, and reduced virus titres in the lung 
infected with highly pathogenic avian influenza 
H5N1 virus (A/Hong Kong/486/97). However, 
phosphoantigen had no protective role against 
another highly pathogenic avian influenza H5N1 
virus infection (A/Hong Kong/483/97); all the 
humanised mice died 9 days after avian influenza 
H5N1 virus infection.
Discussion
Using a humanised mouse model, phosphoantigen 
was demonstrated to control human influenza A 
virus infection in vivo. For avian influenza A virus 
infection, this protection was strain-dependent. 
Phosphoantigen could control avian influenza A 
H5N1/486 but not H5N1/483 virus infection in 
vivo. The control of influenza A virus infection 
may be mediated by the selective activation and 
expansion of human Vδ2-T cells in the humanised 
mouse model. This variance between the different 
strains of H5N1 virus may be explained by the fact 
that H5N1/483 virus can invade mouse brain and 
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cause death, but the human Vδ2-T cells cannot cross 
the brain-blood barrier. Our study suggests a novel 
therapeutic approach against influenza by using 
phosphoantigens to activate and expand γδ−T cells 
against influenza infection.
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